Pharmacological strategies for the prevention of Alzheimer's disease (Q34478669)

2 August 2017

title

Pharmacological strategies for the prevention of Alzheimer's disease (English)

1 reference

2 August 2017

0 references

1 reference

1 reference

P Murali Doraiswamy

1

1 reference

2 August 2017

Glen L Xiong

series ordinal

2

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 January 2006

1 reference

Expert Opinion on Pharmacotherapy

2 August 2017

published in

1 reference

2 August 2017

volume

7

1 reference

2 August 2017

issue

1

1 reference

2 August 2017

page(s)

1-10

1 reference

Non-cholinergic strategies for treating and preventing Alzheimer's disease

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517/14656566.7.1.1

Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.1.1

Vitamin E and donepezil for the treatment of mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.1.1

Glutamate transmission and toxicity in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.1.1

Neuroprotective effect of memantine demonstrated in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.1.1

Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.1.1

A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.1.1

Inflammation, autotoxicity and Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.1.1

A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.1.1

Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.1.1

A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.1.1

The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.1.1

Ginkgo for memory enhancement: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.1.1

Ginkgo for elderly people with dementia and age-associated memory impairment: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.1.1

Recombinant human nerve growth factor infusions prevent cholinergic neuronal degeneration in the adult primate brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.1.1

Sustained improvements in patients with dementia of Alzheimer's type (DAT) 6 months after termination of Cerebrolysin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.1.1

The neuroprotective effects of Cerebrolysin in a transgenic model of Alzheimer's disease are associated with improved behavioral performance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.1.1

MAPK activation via 5-hydroxytryptamine 1A receptor is involved in the neuroprotective effects of xaliproden

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.1.1

Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.1.1

Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.1.1

Alterations of Alzheimer's disease in the cholesterol-fed rabbit, including vascular inflammation. Preliminary observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.1.1

The role of cholesterol in the biosynthesis of beta-amyloid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.1.1

Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.1.1

Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.1.1

Statin use and hippocampal volumes in elderly subjects at risk for Alzheimer's disease: a pilot observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.1.1

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.1.1

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.1.1

Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.1.1

Estrogen receptors colocalize with low-affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.1.1

Estrogen, Cognition, and a Woman’s Risk of Alzheimer’s Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.1.1

Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.1.1

Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.1.1

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.1.1

Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.1.1

Effects of a MAO-B inhibitor in the treatment of Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.1.1

Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.1.1

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.1.1

Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.1.1

Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.1.1

The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.1.1

Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.1.1

Cognitive function after open-heart surgery: are postoperative neuropsychological deficits caused by cardiopulmonary bypass?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.1.1

Microembolic Brain Injuries from Cardiac Surgery: Are They Seeds of Future Alzheimer's Disease?a

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.1.1

Protecting the brains of patients after heart surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.1.1

Cognitive deficits following coronary artery bypass grafting: prevalence, prognosis, and therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.1.1

21 January 2018

Identifiers

DOI

10.1517/14656566.7.1.1

1 reference

2 August 2017

1 reference